ArticleInfection and drug resistance2025
Predicting Healthcare-Associated Infection in Patients with Pneumonia via QuantiFERON
Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: A functional immune system is essential for recovery from pneumonia; hence, measuring and monitoring immune-status indicators is clinically important. This study aimed to determine whether QuantiFERON monitoring (QMF) could predict healthcare-associated infection (HCAI) according to the immune-status of patients with pneumonia. Methods: Prospective, observational, single-center study, patients ≥19 years hospitalized for pneumonia between October 2020 and November 2021. QFM was performed at hospital admission (D1) and seven days after (D2). Data from 90 patients in the D1 QFM group were analyzed, which was further divided into the non-healthcare-associated infection (non-HCAI, n = 41, 45.6%) and HCAI (n = 49, 54.4%) groups. Results: The D1 and D2 QFM levels were both significantly higher in the non-HCAI group than in the HCAI group (D1 hCAI vs non-HCAI: 4.40 vs 5.75 IU/mL, D2 hCAI vs non-HCAI: 4.38 vs 6.10 IU/mL). Analysis of the change in D1 and D2 QFM levels by each group showed that D2 QFM levels increased over D1 QFM levels in the non-HCAI group (5.75 vs 6.10 IU/mL), while D2 QFM levels decreased over D1 QFM levels in the HCAI group (4.40 vs 4.38 IU/mL). D1 QFM was consistently negatively correlated with TNF-α and CRP. The integrated analysis of D1 QFM and CCI and D1 QFM and CURB-65 had fair to predict the occurrence of HCAI. Conclusion: QFM can be used to predict the immune-status of patients in the context of healthcare-associated infections. These findings provide important insights into the current understanding of pneumonia treatment and recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.